

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

**AMELIORATIVE EFFECT OF LEAVES OF *CARICA*  
*PAPAYA* IN ETHANOL AND ANTITUBERCULAR DRUG  
INDUCED HEPATOTOXICITY**

Pandit Aashish, Sachdeva Tarun and Bafna Pallavi\*  
Department of Pharmacology, Rayat Institute of Pharmacy, Railmajra, Punjab

**\*Corresponding Author**

Dr. Pallavi Bafna  
Professor of Pharmacology,  
Rayat Institute of Pharmacy,  
Railmajra, Dist. S.B.S. Nagar,  
Punjab -144533 (INDIA)

20 **ABSTRACT**

21 **Aims:** The leaves of *Carica papaya* Linn. (Caricaceae) have been traditionally used as a medicine against  
22 some forms of liver diseases. Its hepatoprotective activity against hepatotoxicants like CCl<sub>4</sub> and  
23 paracetamol has been scientifically proved in animals. The aim of the present study is to examine the  
24 hepatoprotective effect of *C. papaya* leaves against ethanol and anti-tubercular drug-induced liver  
25 damage, the two clinically relevant animal models.

26 **Study Design:** The aqueous extract of leaves of the plant was administered orally to rats and effects on  
27 hepatic marker enzymes, tissue antioxidants and liver histology were determined.

28 **Place and Duration of Study:** The study was performed in Rayat Institute of Pharmacy, Railmajra, Dist.  
29 S.B.S. Nagar, Punjab, between Dec' 2011 to July 2012.

30 **Materials and Methods:** The study was performed by administering the aqueous extract of *C. papaya*  
31 leaves at the dose of 400 mg/kg in rats prior to administration of ethanol or combination of Isoniazid and  
32 Rifampicin. The effects on the levels of serum indicators of liver damage (SGPT, SGOT, alkaline  
33 phosphatase and total bilirubin) and tissue antioxidant parameters like TBARS, GSH and SOD were  
34 determined. Histopathology of liver was also performed to study the influence of drug on tissue integrity.

35 **Results:** Hepatoprotective activity of leaves of *C. papaya* was evident by the significant reduction in the  
36 levels of all serum markers in both the models. The extract also significantly increased the levels of SOD,  
37 GSH and total protein; and decreased the levels of TBARS, indicating its antioxidant effect. The results  
38 obtained were also confirmed by improvements in the histopathology of liver.

39 **Conclusion:** The results obtained in the current study justify the use of *Carica papaya* leaves in the  
40 treatment of liver damage induced by commonly consumed hepatotoxicants, namely ethanol and anti-  
41 tubercular drugs.

42

43 **Keywords:** *Carica papaya*; leaves; ethanol; hepatotoxicity; antioxidant; histopathology.

44

## 45 1. INTRODUCTION

46 Liver disease is the major cause of death worldwide. It ranks ninth in overall causes of death in the U.S.  
47 [1] and is the fifth 'big killer' in England & Wales. In India too, liver diseases are responsible for lakhs of  
48 deaths each year. It is rather the only major cause of death still increasing year-on-year.

49  
50 Alcoholic liver disease (ALD) is among the leading causes of morbidity and mortality in the world. In an  
51 assessment by the WHO in 2005, 4% of the burden of the disease and 3.2% of all deaths globally were  
52 attributable to alcohol. The burden of alcohol-related disease is highest in the developed world, where it  
53 may account for as much as 9.2% of all disability-adjusted life years [2]. Even in the developing regions of  
54 the world, however, alcohol accounts for a major portion of global disease burden, and is projected to take  
55 on increasing importance in those regions over time [3].

56  
57 Tuberculosis is one of the fatal communicative diseases and is spread easily amongst people. Over one-  
58 third of the world's population is estimated to be infected with *Mycobacterium tuberculosis* and over 2  
59 million people a year die of the disease. The first line anti-tubercular drugs namely, Rifampicin and  
60 Isoniazid are potentially hepatotoxic drugs. Based on hepatotoxicity diagnosis criteria and population  
61 under study, incidence of anti-TB related hepatotoxicity is reported to range from 2% to 28% [4].

62  
63 The available therapeutic interventions for liver diseases, which include drugs like steroids, anti-cytokines,  
64 colchicine or supplementation with calorie rich diet or a precursor of glutathione, S-adenosyl L-methionine  
65 (SAME) have not been able to show convincing benefit in humans and also suffer from several side  
66 effects. Thus herbal medicines have an important role to play in the treatment of liver disorders  
67 considering their efficacy, safety and lesser side effects.

68  
69 A wide range of plants have been utilized for the treatment of multiple disorders of the liver. There are  
70 hundreds of hepatoprotective herbs which are proven for their hepatoprotective action against several  
71 types of hepatotoxins. A few important examples are *Silybum marianum*, *Phyllanthus niruri*, *Andrographis*  
72 *paniculata*, *Picrorrhiza kurroa*, *Eclipta alba* and *Tephrosia purpurea*.

73 *Carica papaya* Linn. is a tropical, herbaceous plant, belonging to family Caricaceae. Traditionally young  
74 leaves have been used in jaundice (as fine paste), urinary complaints, gonorrhoea (as infusion), colic,  
75 fever, beriberi, abortion (as infusion) and in asthma (as smoke). The leaves of *Carica papaya* have been  
76 recently studied against hepatotoxins like CCl<sub>4</sub> [5] and paracetamol [6] and have indicated their  
77 hepatoprotective activity in rats. The leaves of *Carica papaya* have however not been proved for its  
78 efficacy against clinically important and widely ingested hepatotoxicants, namely ethanol and  
79 antitubercular drugs. Thus, the purpose of the present study was to evaluate the hepatoprotective activity  
80 of the aqueous extract of leaves of *Carica papaya* against ethanol and anti-tubercular drug- induced liver  
81 toxicity.

82

## 83 **2. MATERIAL AND METHODS**

### 84 **2.1 Drugs and Chemicals**

85 Silymarin tablets (Silybon-70<sup>®</sup>, Micro Labs Ltd., Himachal Pradesh, India) were purchased from the local  
86 market. All the reagents and chemicals used in the study were of analytical grade and were procured from  
87 Spruce Enterprises (Ambala, Haryana, India). Diagnostic kits for the estimation of serum levels of various  
88 parameters were procured from Avecon Healthcare Pvt. Ltd. (Saha, Haryana, India).

89

### 90 **2.2 Collection of Plant Material**

91 Fresh leaves of *Carica papaya* Linn. (Family: Caricaceae) were collected from the botanical garden of  
92 Rayat Institute of Pharmacy, Railmajra (Punjab). The leaves of *C. papaya* were identified and  
93 authenticated by Dr. S.K. Upadhyay, Department of Horticulture, CSK Himachal Pradesh Agriculture  
94 University, Palampur, Himachal Pradesh (India).

95

### 96 **2.3 Preparation of Extract**

97 The leaves were washed with water to eliminate any dead matter and other unwanted particles and then  
98 air-dried for 3 weeks. The dried leaves were then ground into a coarse powder, which was then boiled in  
99 distilled water for an hour, and subsequently filtered through Whatman filter paper (No.1). The filtered  
100 solution was then heated at 60<sup>o</sup>–70<sup>o</sup>C to yield a concentrated solution, which was then vacuum dried. The

101 percentage yield was found to be 10.5%. The aqueous extract of *C. papaya* leaves (AECPL) was  
102 dissolved in distilled water and prepared fresh for the experiments.

103

## 104 **2.4 Phytochemical evaluation**

105 Phytochemical evaluation of aqueous extract of leaves of *Carica papaya* (AECPL) was carried out as per  
106 standard methods [7, 8].

107

## 108 **2.5 Experimental animals**

109 Albino Wistar rats of either sex (weighing 150-180 g) were used for the experiments. The animals were  
110 housed in polypropylene cages under standard conditions (Temperature:  $28 \pm 2^\circ\text{C}$ , Relative humidity:  $50 \pm$   
111  $2\%$ , 12 hr light / dark cycle) and provided with standard pellet diet and water *ad libitum*. The experimental  
112 protocols were approved by the Institutional Animal Ethics Committee and conducted according to the  
113 guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals  
114 (CPCSEA), New Delhi, India.

115

## 116 **2.6 Grouping of Animals**

117 Animals were divided into four groups of six animals each. Group 1 represented the normal control group  
118 that received the vehicle, distilled water (5ml/kg, p.o.). Group 2 represented the negative control group  
119 which received the vehicle, distilled water (5ml/kg, p.o.) followed by administration of the hepatotoxicant.  
120 Group 3 represented the drug treated group which received the aqueous extract of leaves of *Carica*  
121 *papaya* (AECPL) at the dose of 400 mg/kg (p.o.). Group 4 served as the standard drug treated group,  
122 which received silymarin at the dose of 200 mg/kg (p.o.).

123

## 124 **2.7 Experimental Methodology**

### 125 **2.7.1 Ethanol induced hepatotoxicity**

126 The method of Zhang et al. [9] was adopted with slight modification. The rats were fasted overnight. All  
127 the animals received the treatment (single dose) as mentioned above, which was followed 1 hr later by  
128 administration of absolute ethanol (4.5 ml/kg, p.o.) to animals of Groups 2, 3 and 4. After 18 hrs of ethanol

129 administration, blood was collected by the retro-orbital plexus method and serum was separated for the  
130 estimations of SGPT, SGOT, ALP and total bilirubin. The animals were then sacrificed and the liver was  
131 dissected out, weighed and homogenized (Homogenizer REMI RQM-122, Remi Instrument, India) in  
132 chilled phosphate buffer (50 mM, pH 7.4) to give a concentration of 10% w/v. The resultant homogenate  
133 was then centrifuged at 4°C and the clear supernatant was collected. This supernatant was then used for  
134 assays of TBARS (Thiobarbituric acid reactive substance), superoxide dismutase (SOD), reduced  
135 glutathione (GSH) and proteins. Histopathological studies on liver were also carried out.

136

### 137 **2.7.2 Antitubercular drugs- induced hepatotoxicity**

138 The method of Jiang *et al.* [10] and Saleem *et al.* [11] was adopted. Briefly, the animals were pretreated  
139 for a period of 10 days. During the 10 days of drug treatment the animals of Groups 2, 3 and 4 received  
140 the combination of anti-tubercular drugs (Isoniazid and Rifampicin) at the dose of 125 mg/100g (i.p.) 1 h  
141 after the administration of the drugs. On the 10<sup>th</sup> day, one hour after administration of the last dose of the  
142 anti-tubercular drugs, blood was collected and serum was separated for determining the levels of SGPT,  
143 SGOT, ALP and total bilirubin. The liver was also removed and processed as mentioned above. The clear  
144 supernatant was then used for assays of TBARS (Thiobarbituric acid reactive substances), reduced  
145 glutathione (GSH) and proteins. Histopathological studies on liver were also carried out.

146

### 147 **2.8 Tissue Estimations**

148 The quantitative measurement of thiobarbituric acid reactive substances (TBARS), which is an index of  
149 extent of lipid peroxidation, was performed according to the method of Ohkawa *et al.* [12]. The levels of  
150 reduced glutathione (GSH) and Superoxide dismutase (SOD) were determined as per the methods of  
151 Beutler *et al.* [13] and Misra and Fridovich [14], respectively. The total protein content in the supernatant  
152 was determined by Lowry's method [15].

153

### 154 **2.9 Histological studies**

155 The liver was excised quickly and fixed in 10% buffered-formaldehyde at room temperature. After  
156 dehydration using graded ethanol, pieces of tissues were embedded in paraffin, cut into fine (5 µm)

157 sections and mounted on glass slides. Sections were then deparaffinized with xylene, counterstained with  
158 hematoxylin and eosin and viewed under a light microscope at 200 X.

159

## 160 **2.10 Statistical Evaluation**

161 The results were expressed as Mean  $\pm$  SEM. Statistical analysis was carried out by using One-way  
162 analysis of variance (ANOVA) followed by Tukey's multiple comparison test, with the level of significance  
163 set at  $P < 0.05$ .

164

## 165 **3. RESULTS**

166

### 167 **3.1 Preliminary Phytochemical Analysis of AECPL**

168 The results of the preliminary phytochemical screening of AECPL have been presented in Table 1.  
169 AECPL showed the presence of alkaloids, flavonoids, reducing sugar, saponins and tannins.

170 **Table 1. Phytochemical Screening of aqueous extract of *Carica papaya* leaves (AECPL)**

| Sr. No. | TEST           | PRESENT (+) / ABSENT (-) |
|---------|----------------|--------------------------|
| 1.      | Alkaloids      | +                        |
| 2.      | Flavonoids     | +                        |
| 3.      | Reducing Sugar | +                        |
| 5.      | Saponins       | +                        |
| 6.      | Tannins        | +                        |
| 7.      | Glycosides     | -                        |
| 8.      | Steroids       | -                        |
| 9.      | Triterpenoids  | -                        |

171

172

173 **3.2 Effects of AECPL in Ethanol-Induced Hepatotoxicity Model**

174 **3.2.1. Serum Parameters**

175 Ethanol administration in the negative control group (Group 2) animals resulted in hepatic damage as  
 176 evidenced by a significant ( $P < 0.001$ ) increase in the levels of SGPT, SGOT, ALP and total bilirubin as  
 177 compared to the normal control group (Group 1). Administration of AECPL to animals of Group 3 showed  
 178 a significant ( $P < 0.001$ ) reduction in the levels of SGPT, SGOT, ALP and total bilirubin when compared to  
 179 the negative control group (Group 2). The effect produced by administration of 400 mg/kg of AECPL was  
 180 found to be similar ( $P > 0.05$ ) to that produced by 200 mg/kg of Silymarin (Table 2).

181  
 182 **Table 2. Effect of aqueous extract of *Carica papaya* leaves (AECPL) on Serum Parameters**  
 183 **in Ethanol Induced Hepatotoxicity Model in Rats**

| GROUPS  | SGPT (U/L)                    | SGOT (U/L)                    | ALP (mg/dl)                  | TOTAL                      |
|---------|-------------------------------|-------------------------------|------------------------------|----------------------------|
|         |                               |                               |                              | BILIRUBIN (mg/dl)          |
| Group 1 | 37.51 ± 0.55                  | 31.40 ± 0.50                  | 28.82 ± 0.22                 | 0.39 ± 0.03                |
| Group 2 | 311.80 ± 26.02 <sup>###</sup> | 201.00 ± 12.32 <sup>###</sup> | 117.20 ± 1.87 <sup>###</sup> | 1.33 ± 0.05 <sup>###</sup> |
| Group 3 | 69.82 ± 0.56 <sup>***</sup>   | 88.29 ± 1.33 <sup>***</sup>   | 39.05 ± 0.06 <sup>***</sup>  | 0.68±0.03 <sup>***</sup>   |
| Group 4 | 57.21 ± 2.25 <sup>***</sup>   | 69.00 ± 7.17 <sup>***</sup>   | 33.79 ± 1.59 <sup>***</sup>  | 0.54 ± 0.05 <sup>***</sup> |

184 All values are expressed as Mean ± SEM. <sup>###</sup> $P < .001$  when compared with Normal Control group (Group 1), <sup>\*\*\*</sup> $P < .001$  when compared with

185 Negative Control group (Group 2)

186 **3.2.2. Tissue Parameters**

187 As regards to the tissue parameters, ethanol administration in negative control group (Group 2) animals  
 188 showed a significant ( $P < 0.001$ ) decrease in the levels of SOD, GSH and total protein; whereas the level  
 189 of TBARS was found to be significantly ( $P < 0.001$ ) increased as compared to normal control group  
 190 (Group 1). Treatment of AECPL to the Group 3 animals showed a significant rise in the levels of SOD ( $P <$   
 191  $0.01$ ), GSH ( $P < 0.001$ ) and total protein ( $P < 0.001$ ); whereas the level of TBARS was found to be



192 significantly ( $P < 0.001$ ) lowered as compared to the negative control group (Group 2). Silymarin  
 193 administration in the Group 4 animals showed a significant ( $P < 0.001$ ) increase in the levels of SOD, GSH  
 194 and total protein; whereas the level of TBARS was found to be significantly ( $P < 0.001$ ) reduced as  
 195 compared to negative control group (Group 2). The effects produced on levels of TBARS and GSH by  
 196 administration of 400 mg/kg of AECPL (Group 3) were found to be similar to that produced by Silymarin  
 197 (Table 3).

198  
 199 **Table 3. Effect of Aqueous extract of *Carica papaya* leaves (AECPL) on Tissue Parameters**  
 200 **in Ethanol Induced Hepatotoxicity Model in Rats**


| GROUPS  | TBARS<br>(nmoles/mg protein)    | SOD<br>(Units/mg protein)      | GSH<br>( $\mu$ M/mg protein)   | TOTAL<br>PROTEIN (mg/g wet tissue) |
|---------|---------------------------------|--------------------------------|--------------------------------|------------------------------------|
| Group 1 | 10.60 $\pm$ 0.50                | 4.35 $\pm$ 0.15                | 1.83 $\pm$ 0.05                | 2.75 $\pm$ 0.06                    |
| Group 2 | 43.33 $\pm$ 1.10 <sup>###</sup> | 1.61 $\pm$ 0.14 <sup>###</sup> | 0.74 $\pm$ 0.03 <sup>###</sup> | 1.48 $\pm$ 0.06 <sup>###</sup>     |
| Group 3 | 22.02 $\pm$ 0.19 <sup>***</sup> | 2.66 $\pm$ 0.19 <sup>**</sup>  | 1.32 $\pm$ 0.01 <sup>***</sup> | 2.18 $\pm$ 0.03 <sup>***</sup>     |
| Group 4 | 16.75 $\pm$ 0.41 <sup>***</sup> | 3.72 $\pm$ 0.04 <sup>***</sup> | 1.74 $\pm$ 0.04 <sup>***</sup> | 2.45 $\pm$ 0.03 <sup>***</sup>     |

201 All values are expressed as Mean  $\pm$  SEM. ### $P < .001$  when compared with Normal Control group (Group 1), \*\* $P < .01$ ; \*\*\* $P < .001$  when compared  
 202 with Negative Control group (Group 2)

203 **3.2.3. Histopathological Changes**

204 In the vehicle-treated normal control group (Group 1) animals, hepatocytes showed a normal lobular  
 205 architecture arranged in the form of cords and the presence of slight vascular congestion and a central  
 206 vein [Fig.1.(A)]; whereas in the negative control group (Group 2) animals, the hepatocytes showed  
 207 feathery degeneration and microcellular fatty changes, along with presence of inflammatory cells around  
 208 the portal tract and high vascular congestion [Fig.1.(B)]. In the liver of animals which were treated with  
 209 AECPL (Group 3) the hepatocytes showed minimal microcellular fatty changes and slight vascular  
 210 congestion [Fig. 1.(C)]. In the silymarin treated group (Group 4) the liver sections showed slight vascular

211 congestion and the hepatocytes were found to be arranged in the form of cords, similar to that in the  
 212 normal control group [Fig.1.(D)].



225 **Fig. 1. Histopathological Studies of Liver in Ethanol Induced Hepatotoxicity**

226 (A) Normal Control (Group 1); (B) Negative Control (Group 2); (C) AECPL + Ethanol (Group 3); (D) Silymarin +  
 227 Ethanol (Group 4)

228

229 **3.3. Effects of AECPL in Antitubercular Drugs Induced Hepatotoxicity Model**

230 **3.3.1 Serum Parameters**

231 Administration of the anti-tubercular drug combination (INH+RIF) in the negative control group (Group 2)  
 232 animals resulted in a significant ( $P < 0.001$ ) increase in the levels of SGPT, SGOT, ALP and total bilirubin  
 233 when compared to the normal control group (Group 1). Administration of AECPL to animals of Group 3

234 showed a significant ( $P < 0.001$ ) reduction in the levels of SGPT, SGOT, ALP and total bilirubin as  
 235 compared to the negative control group (Group 2). Similarly a significant ( $P < 0.001$ ) reduction in the  
 236 levels of all serum parameters was observed in the Silymarin treated Group 4 animals as compared to the  
 237 negative control group (Group 2). The effect produced by administration of AECPL was found to be similar  
 238 (Non-significant;  $P > 0.05$ ) to that produced by 200 mg/kg of Silymarin (Table 4).

239

240 **Table 4. Effect of aqueous extract of *Carica papaya* leaves (AECPL) on Serum Parameters**  
 241 **in Anti-tubercular drugs Induced Hepatotoxicity Model in Rats**

| GROUPS  | SGPT (U/L)                    | SGOT (U/L)                    | ALP (mg/dl)                   | TOTAL                      |
|---------|-------------------------------|-------------------------------|-------------------------------|----------------------------|
|         |                               |                               |                               | BILIRUBIN (mg/dl)          |
| Group 1 | 37.51 ± 0.55                  | 31.40 ± 0.50                  | 28.82 ± 0.22                  | 0.39 ± 0.03                |
| Group 2 | 218.80 ± 14.70 <sup>###</sup> | 308.40 ± 18.16 <sup>###</sup> | 251.90 ± 10.78 <sup>###</sup> | 1.71 ± 0.05 <sup>###</sup> |
| Group 3 | 139 ± 5.53 <sup>***</sup>     | 175.3 ± 4.4 <sup>***</sup>    | 150.5 ± 5.7 <sup>***</sup>    | 0.82 ± 0.05 <sup>***</sup> |
| Group 4 | 108.90 ± 4.19 <sup>***</sup>  | 138.90 ± 4.61 <sup>***</sup>  | 124.00 ± 4.2 <sup>***</sup>   | 0.63 ± 0.03 <sup>***</sup> |

242 All values are expressed as Mean ± SEM. <sup>###</sup> $P < .001$  when compared with Normal Control group (Group 1), <sup>\*\*\*</sup> $P < .001$  when compared with  
 243 Negative Control group (Group 2)

244 **3.3.2. Tissue Parameters**

245 Antitubercular drugs (INH+RIF) administration in negative control group (Group 2) animals showed a  
 246 significant ( $P < 0.001$ ) decrease in the levels of SOD, GSH and total protein; whereas the level of TBARS  
 247 was found to be significantly ( $P < 0.001$ ) increased as compared to normal control group (Group 1).  
 248 Treatment of AECPL to the Group 3 animals showed a significant rise in the levels of GSH ( $P < 0.01$ ) and  
 249 total protein ( $P < 0.01$ ); whereas the level of TBARS was found to be significantly ( $P < 0.01$ ) lowered as  
 250 compared to the negative control group (Group 2). Silymarin administration in the Group 4 animals  
 251 showed a significant ( $P < 0.001$ ) increase in the levels of SOD, GSH and total protein; whereas the level  
 252 of TBARS was found to be significantly ( $P < 0.001$ ) reduced as compared to negative control group

253 (Group 2). The effects produced on levels of TBARS and GSH by administration of AECPL (Group 3)  
 254 were found to be similar to that produced by Silymarin (Table 5).

255  
 256 **Table 5. Effect of Aqueous extract of *Carica papaya* leaves (AECPL) on Tissue Parameters**  
 257 **in Anti-tubercular drugs Induced Hepatotoxicity Model in Rats**

| GROUPS  | TBARS<br>(nmoles/mg protein)    | GSH<br>( $\mu$ M/mg protein)   | TOTAL PROTEIN<br>(mg/g wet tissue) |
|---------|---------------------------------|--------------------------------|------------------------------------|
| Group 1 | 10.60 $\pm$ 0.51                | 1.83 $\pm$ 0.05                | 2.68 $\pm$ 0.06                    |
| Group 2 | 52.53 $\pm$ 1.08 <sup>###</sup> | 0.54 $\pm$ 0.02 <sup>###</sup> | 1.37 $\pm$ 0.04 <sup>###</sup>     |
| Group 3 | 34.03 $\pm$ 0.7 <sup>**</sup>   | 0.75 $\pm$ 0.02 <sup>**</sup>  | 1.70 $\pm$ 0.01 <sup>**</sup>      |
| Group 4 | 22.14 $\pm$ 0.32 <sup>***</sup> | 1.48 $\pm$ 0.04 <sup>***</sup> | 2.01 $\pm$ 0.05 <sup>***</sup>     |

258 All values are expressed as Mean  $\pm$  SEM. ###  $P < .001$  when compared with Normal Control group (Group 1); \*\*  $P < .01$ ; \*\*\*  $P < .001$  when compared  
 259 with Negative Control group (Group 2)


260 **3.3.3. Histopathological Changes**

261 In the vehicle-treated normal control group (Group 1) animals, hepatocytes showed a normal lobular  
 262 architecture arranged in the form of cords, presence of slight vascular congestion and a central vein  
 263 **[Fig.2.(A)]**; whereas in the negative control group (Group 2) animals, hepatocytes showed feathery  
 264 degeneration, microcellular fatty changes, portal triaditis and vascular congestion in the liver **[Fig.2.(B)]**. In  
 265 the AECPL treated group (Group 3) the hepatocytes showed a minimal vascular congestion with  
 266 moderate portal triaditis and microcellular fatty changes **[Fig. 2.(C)]**. In the silymarin treated group (Group  
 267 4) the liver sections showed a slight vascular congestion and normal lobular architecture, similar to that in  
 268 the normal control group **[Fig.2.(D)]**.

269

270





285 **Fig. 2. Histopathological Studies of Liver in Anti-Tubercular Drugs (INH + RIF) induced**  
 286 **Hepatotoxicity Model**

287 *(A) Normal Control (Group 1); (B) Negative Control (Group 2); (C) AECPL + INH + RIF (Group 3); (D) Silymarin + INH*  
 288 *+ RIF (Group 4)*

289

290 **4. DISCUSSION**

291 The liver is responsible for processing most of the chemicals and medications that enter the body; thus  
 292 leaving it vulnerable to acute or chronic liver diseases caused by chemicals. In some cases, this is a  
 293 predictable consequence of over-consumption of certain chemicals such as acetaminophen and some  
 294 prescription medications, including antibiotics, non-steroidal anti-inflammatory drugs and anti-convulsants;  
 295 or due to exposure to industrial toxins like polyvinyl chloride or carbon tetrachloride (CCl<sub>4</sub>). Other causes  
 296 of liver diseases are excessive alcohol consumption, vascular diseases, rare metabolic diseases such as

297 Wilson's disease, obesity and congenital birth defects. The efficacy of any hepatoprotective drug is  
298 essentially dependent on its capability to either reduce the harmful effects or to maintain the normal  
299 hepatic physiological mechanisms which has been unbalanced by the hepatotoxins.

300  
301 *Carica papaya* is a tropical plant belonging to family Caricaceae. The *Carica papaya* fruit [16] and seeds  
302 [17] have been scientifically proved in animals for its significant hepatoprotective activity against CCl<sub>4</sub>. The  
303 aqueous extract of leaves of *C.papaya* at the doses of 200 and 400 mg/kg (p.o.) has been evaluated  
304 earlier for its hepatoprotective activity against CCl<sub>4</sub>- induced hepatotoxicity in rats [5]. Results showed that  
305 the extract caused significant and dose-dependent decrease in the serum levels of SGPT, SGOT, ALP,  
306 bilirubin and serum MDA. It was also observed that maximum hepatoprotection was offered at the oral  
307 dose of 400 mg/kg of the extract. Venugopalan et al. [6] also studied the leaf extract of *C.papaya* at an  
308 oral dose of 400 mg/kg against paracetamol induced liver damage and found significant hepatoprotection.  
309 Thus, the earlier studies suggested that *C.papaya* possesses potent hepatoprotective activity in  
310 experimental animals.

311  
312 The leaves of *Carica papaya* have however not been proved for its efficacy against other important  
313 hepatotoxins. Thus, the purpose of the present study was to evaluate the hepatoprotective activity of the  
314 aqueous extract of leaves of *Carica papaya* against ethanol induced- and anti-tubercular drug induced-  
315 liver damage in rats. The dose selected for the present study was 400 mg/kg (p.o.) as this dose has been  
316 proved to be the most effective hepatoprotective dose against the hepatotoxicants studied earlier.

317  
318 The metabolic activation and biochemical mechanisms of hepatotoxicity induced by ethanol have been  
319 reviewed earlier [18]. Ethanol produces a constellation of dose-related deleterious effects in the liver.  
320 Alcohol ingestion is documented to cause fatty infiltration, hepatitis and cirrhosis. Oxidative stress is one  
321 major factor in the etiology of ethanol induced injury, mainly by Kupffer cell derived reactive oxygen  
322 species (ROS). Ethanol activates the Kupffer cells primarily through the action of a substance called  
323 endotoxin, which is released by certain gram negative bacteria present in the intestine. The activation of  
324 Kupffer cells generates ROS and proinflammatory cytokines (TNF alpha, IL-1), both leading to liver

325 damage. Hepatitis and cirrhosis may occur due to higher lipid peroxidative reaction during the microsomal  
326 breakdown of ethanol. Increased formation of lipoperoxides, conjugated dienes and malondialdehyde  
327 (MDA) and reduced levels of antioxidants like vitamin E and glutathione in the tissues have been  
328 demonstrated in experimental animals administered with ethanol as well as alcoholic human subjects. In  
329 the present study, a single dose administration of ethanol (4.5 ml/kg, p.o.) caused a significant ( $P < 0.001$ )  
330 increase in the levels of SGPT, SGOT, ALP and total bilirubin, serum indicators of hepatic damage. It was  
331 also accompanied by an increase in the level of tissue TBARS and marked reduction in the levels of GSH  
332 and SOD which indicated the presence of oxidative stress.

333 Anti-tubercular drugs like Isoniazid (INH) and Rifampicin (RIF) when given in combination enhances their  
334 toxic effect. Hepatocytes of the INH + RIF generally show liver cell necrosis and inflammation in  
335 experimental animals [19]. INH is metabolized to mono-acetyl hydrazine (AcHz), which is further  
336 metabolized to a toxic product by cytochrome P450, leading to hepatotoxicity. Patients on concurrent  
337 rifampicin therapy have an increased incidence of hepatitis. This has been postulated due to rifampicin-  
338 induced cytochrome P450 enzyme induction, causing an increased production of the toxic metabolites  
339 from acetyl-hydrazine (AcHz). Rifampicin also increases the metabolism of INH to isonicotinic acid and  
340 hydrazine, both of which are hepatotoxic. The plasma half life of AcHz (metabolite of INH) is shortened by  
341 rifampicin and AcHz is quickly converted to its active metabolites by increasing the oxidative elimination  
342 rate of AcHz, which is related to the higher incidence of liver necrosis caused by INH and rifampicin in  
343 combination. Rifampicin is also known to induce the hydrolysis pathway of INH metabolism into the  
344 hepatotoxic metabolite hydrazine [20]. The generation of oxidative stress was also found to play a role in  
345 liver damage induced by anti-tubercular drugs. In the present study too, administration of combination of  
346 INH + RIF at the dose of 125 mg/kg (i.p.) for 10 days to rats showed significant ( $P < 0.001$ ) increase in the  
347 levels of hepato-specific enzymes like SGPT, SGOT, ALP and total bilirubin when compared to the normal  
348 control group, indicating liver damage. Similarly, increase in the extent of lipid peroxidation (TBARS) and  
349 reduction in the GSH level indicated the presence of oxidative damage.

350 In the present study, treatment of rats with aqueous extract of leaves of *Carica papaya* (AECPL) at the  
351 dose of 400 mg/kg (p.o.) in both the animal models significantly ( $P < 0.001$ ) decreased the levels of

352 SGPT, SGOT, ALP and total bilirubin in the serum, which indicated its hepatoprotective effect. Also the  
353 extract was found to reduce the level of TBARS and increase the levels of GSH and SOD, revealing the  
354 antioxidant nature of the extract.

355 *Silybum marianum* (Milk thistle; Family: Asteraceae/Compositae) is one of the oldest and thoroughly  
356 researched plants in the treatment of liver diseases. It has been proved for its effectiveness against  
357 ethanol- induced hepatotoxicity model in rats [21] and antitubercular drugs induced hepatotoxicity [22].  
358 Recently, several studies have been carried out to elucidate the mechanism of action of silymarin.  
359 Accumulated data show that this herbal drug potentiates the antioxidant capacity of the liver, acts as a  
360 scavenger of oxygen free radicals [23], inhibits the synthesis of pro-inflammatory cytokines [24], in  
361 addition to its hepatoprotective actions. In the present study, silymarin administration in rats at the dose of  
362 200 mg/kg significantly ( $p < 0.001$ ) lowered the levels of serum liver markers (SGPT, SGOT, ALP and total  
363 bilirubin); and increased the antioxidant parameters (GSH and SOD) while it reduced the level of TBARS  
364 in the liver tissue. Also, the effects produced by 400 mg/kg of aqueous extract of *Carica papaya* leaves  
365 were found to be comparable to that of the standard drug, silymarin (200 mg/kg, p.o.).

366 The results were further confirmed by histopathological studies. The liver sections of animals exposed to  
367 hepatotoxicants, namely ethanol and anti-tubercular drugs showed histological changes which were  
368 similar to those reported earlier by many researchers. In the animals treated *Carica papaya* or Silymarin,  
369 the hepatocytes showed restoration or preservation of the normal tissue architecture. This proved the  
370 ameliorative effect of *Carica papaya* leaves against ethanol-induced and anti-tubercular drugs induced  
371 hepatotoxic changes.

372 In the present study, preliminary phytochemical studies of the aqueous extract of leaves of *Carica papaya*  
373 showed the presence of flavonoids, alkaloids and saponins. Literature review revealed that the  
374 hepatoprotective activity of herbal drugs is due to the presence of different chemical constituents like  
375 flavonoids [25, 26], alkaloids [27], triterpenoids [28], and saponins [29]. It has also been reported that  
376 flavonoids are able to inhibit drug-induced hepatotoxicity in experimental models due to their potent anti-  
377 oxidant or free radical scavenging properties [30, 31]. In addition, literature [32] has shown that alkaloids



378 elicit hepatoprotective activity by strongly inhibiting lipid peroxidation (by reduction of malondialdehyde  
379 production) and cell membrane disruption (reduction of lactate dehydrogenase leakage induced in isolated  
380 hepatocytes). The leaves of *Carica papaya* also contain vitamin C (ascorbic acid) and carotene, which are  
381 well documented for their antioxidant activities [33]. These antioxidants along with flavonoids and alkaloids  
382 may have counteracted the free radicals through effective scavenging.

383 Also, vitamin C has been proved for its liver protective actions against various hepatotoxicants like  
384 thioacetamide-induced cirrhosis model in rats [34] and lead-induced liver damage [35]. Recently, Dutta et  
385 al. [36] have also proved the protective role of ascorbic acid (Vit C) against alcohol induced hepatotoxicity.  
386 This thus indicates that the presence of these natural antioxidants and hepatoprotective substances in  
387 *Carica papaya* leaves may play an important role in hepatoprotection.

## 388 **5. CONCLUSION**

389 The study thus concludes that the leaves of *Carica papaya* possess hepatoprotective activity, which may  
390 be partly due to its antioxidant effect. It also suggests that *Carica papaya* leaves are a promising  
391 candidate for the development of phytomedicine and can be used in herbal formulations alone or in  
392 combination with other hepatoprotective drugs (to provide a synergistic effect) for the treatment of liver  
393 ailments. Further, studies in humans are needed in this direction to prove its clinical utility.

394

## 395 **ACKNOWLEDGEMENTS**

396 The authors would like to thank The Director, Rayat Institute of Pharmacy, Railmajra (Punjab) for  
397 providing the necessary facilities for the research work; Dr. Prashant Jain, MD (Pathology) for rendering  
398 help in performing the histopathological studies and Dr. S.K. Upadhyay, Department of Horticulture, CSK  
399 Himachal Pradesh Agriculture University, Palampur, Himachal Pradesh (India) for authentication of the  
400 plant material.

## 401 **COMPETING INTERESTS**

402 The authors declare no competing interest.

403  
404 **AUTHORS' CONTRIBUTIONS**  
405  
406 Mr. Aashish Pandit did the literature survey, designed the study, performed the statistical analysis and  
407 wrote the first draft of the manuscript. Mr. Tarun Sachdeva helped Mr. Aashish to perform the study and  
408 carry out the analysis of the data. Dr. Pallavi Bafna helped in designing the study and checking the  
409 manuscript. All authors have read and approved the final manuscript.

410

411 **CONSENT**

412 Not applicable

413

414 **ETHICAL APPROVAL**

415 Experiments have been examined and approved by the Institutional Animal Ethical Committee (IAEC) and  
416 have therefore been performed in accordance with the ethical standards.

417

418 **REFERENCES**

- 419 [1] Bell BP, Navarro VJ, Manos MM, Murphy RC, Leyden WA, St. Louis TE, et al. The epidemiology of  
420 newly diagnosed chronic liver diseases in the United States: Findings of population-based sentinel  
421 surveillance. *Hepatology*. 2001;34:468A.
- 422 [2] Ezzati M, Lopez A, Rodgers A, Vander-Hoorn S, Murray C. Selected major risk factors and global and  
423 regional burden of disease. *Lancet*. 2002;360:1347-60.
- 424 [3] World Health Organization. Global status report on alcohol 2004. Geneva, Switzerland; 2004.
- 425 [4] Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and  
426 pyrazinamide. *Tubercle*. 1978;59:13-32.
- 427 [5] Mohammed A, Abubakar SA, Sule MS. Hepatoprotective effect of aqueous leaf extract of *Carica*  
428 *papaya* Linn against CCl<sub>4</sub> induced hepatic damage in rats. *Int J Pharm Sci Rev Res*. 2011;11:13-6.
- 429 [6] Venugopalan R, Perumal P, Gaddam R, Rajagoundan R. Hepatoprotective and *in vivo* antioxidant  
430 activity of methanol extract of *Carica papaya* Linn. leaves on paracetamol -induced liver damage in rats. *J*  
431 *Pharm Res*. 2012;5:3085-91.
- 432 [7] Trease GE and Evans WC. A Text book of Pharmacognosy. 13th ed. London: Bailliere Tindall Ltd.;  
433 1989.
- 434 [8] Khandelwal KR. Practical Pharmacognosy techniques and experiments. 12th ed. Pune: Nirali  
435 Prakashan; 2004.
- 436 [9] Zhang P, Bagby GJ, Xie M, Stoltz DA, Summer WR, Nelson S. Acute ethanol intoxication inhibits  
437 neutrophil beta 2-integrin expression in rats during endotoxemia. *Alcohol Clin Exp Res*. 1998;22:135-41.
- 438 [10] Jiang Y, Renxiu P, Jing Y, Rui K, Juan L. CYP2E1 mediated Isoniazid-induced hepatotoxicity in rats.  
439 *Acta Pharmacol Sin*. 2004;25:699-704.
- 440 [11] Saleem MTS, Christina AJM, Chidambaranathan N, Ravi V, Gauthaman K. Hepatoprotective activity  
441 of *Annona squamosa* on experimental animal model. *Int J Appl Res Nat Pro*. 2008;1:1-7.
- 442 [12] Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid  
443 reaction. *Anal Biochem*. 1979;95:351-8.
- 444 [13] Beutler E, Duron O, Kellin BM. Improved method for the determination of blood glutathione. *J Lab Clin*  
445 *Med*. 1963;61:882-8.

- 446 [14] Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple  
447 assay for superoxide dismutase. *J Biol Chem.* 1972;247:3170-5.
- 448 [15] Lowry OH, Rosebrough NH, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent.  
449 *J Bio Chem.* 1951;193:265-75.
- 450 [16] Raj Kapoor B, Jayakar B, Kavimani S, Murugesh N. Effect of dried fruits of *Carica papaya* Linn. on  
451 hepatotoxicity. *Biol Pharm Bull.* 2002;25:1645-6.
- 452 [17] Adeneye AA, Olagunju JA, Banjo AAF, Abdul SF, Sanusi OA, Sanni OO, et al. The aqueous seed  
453 extract of *Carica papaya* Linn prevents carbon tetrachloride induced hepatotoxicity in rats. *Int J App Res*  
454 *Nat Prod.* 2009;2:19-32.
- 455 [18] Tsukamoto H, Kaplowitz N. Pathogenesis of alcoholic liver disease. In: *Liver and Biliary Diseases*,  
456 Kaplowitz N, editor. Baltimore: Williams and Wilkins; 1996.
- 457 [19] Ravi V, Patel SS, Verma NK, Dutta D, Saleem TSM. Hepatoprotective Activity of *Bombax ceiba* Linn  
458 against Isoniazid and Rifampicin-induced Toxicity in Experimental Rats. *Int J App Res Nat Prod.*  
459 2010;3:19-26.
- 460 [20] Padma VV, Suja V, Shyamala DCS. Hepatoprotective effect of Liv-52 on antitubercular drug-induced  
461 hepatotoxicity in rats. *Fitoterapia.* 1998;69:520-2.
- 462 [21] Das SK, Vasudevan DM. Protective effects of silymarin, a milk thistle (*Silybium marianum*) derivative  
463 on ethanol-induced oxidative stress liver in liver. *Ind J Biochem Biophys.* 2006;43:306-11.
- 464 [22] Bansal S, Tekur U, Chaturvedi UK, Gupta VK. Hepatoprotective Effect of silymarin against  
465 hepatotoxicity induced by anti-tubercular drugs in malnourished rats. *The Faseb J.* 2007;21:729.
- 466 [23] Lu ZM, Tao WY, Zou XL, Fu HZ, Ao ZH. Protective effects of mycelia of *Antrodia camphorata* and  
467 *Armillariella tabescens* in submerged culture against ethanol-induced hepatic toxicity in rats. *J*  
468 *Ethnopharmacol.* 2007;110:160-4.
- 469 [24] Huang GJ, Deng JS, Chiu CS, Liao JC, Hsieh WT, Sheu MJ, et al. Hispolon protects against acute  
470 liver damage in the rat by inhibiting lipid peroxidation, proinflammatory cytokine, and oxidative stress and  
471 down regulating the expressions of iNOS, COX-2, and MMP-9. *Evid-Based Compl Alt Med.* 2012;2012:1-  
472 12.

- 473 [25] Paya M, Ferrandiz ML, Sanz MJ, Alcaraz MJ. Effects of phenolic compounds on bromobenzene  
474 mediated hepatotoxicity in mice. *Xenobiotica*. 1993;23:327-33.
- 475 [26] Carini R, Comoglio A, Albano E, Poli G. Lipid peroxidation and irreversible damage in the rat  
476 hepatocytes model: Protection by the silybin-phospholipid complex IdB 1016. *Biochem Pharmacol*. 1992;  
477 38: 2859-2865.
- 478 [27] Manjunatha BK, Mankani KL, Vidya SM, Krishna V, Manohara YN. Hepatoprotective activity of *Butea*  
479 *superba* against carbon tetrachloride induced hepatic damage in rodents. *Pharmacog Mag*. 2008;4:41-5.
- 480 [28] Gao J, Tang X, Dou H, Fan Y, Zhao X, Xu Q. Hepatoprotective activity of *Terminalia catappa* Linn.  
481 leaves and its two triterpenoids. *J Pharm Pharmacol*. 2004;56:1449-55.
- 482 [29] Tran QL, Adnyana IK, Tezuka Y, Nagaoka QK, Tran, Kadota S. Triterpene saponins from Vietnamese  
483 ginseng (*Panax vietnamensis*) and their hepatocyte protective activity. *J Nat Prod*. 2001;64:456-61.
- 484 [30] Fraga CG, Martino VS, Ferraro GE, Coussio JD, Boveris A. Flavonoids as antioxidants evaluated by  
485 *in vitro* and *in situ* liver chemiluminescence. *Biochem Pharmacol*. 1987;36:717-20.
- 486 [31] Laughton MJ, Halliwell B, Evans PJ, Hoult JRS. Antioxidant and pro-oxidant actions of the plant  
487 phenolics quercetin, gossypol and myristicin effects on lipid peroxidation, hydroxyl radical generation and  
488 bleomycin-dependent damage to DNA. *Biochem Pharmacol*. 1989;38:2859-65.
- 489 [32] Lanhers MC, Joyeux M, Soulimani R, Fleurentin J, Sayag M, Mortier F, et al. Hepatoprotective and  
490 anti-inflammatory effects of a traditional medicinal plant of Chile, *Pneumus boldus*. *Planta Med*.  
491 1991;57:110-5.
- 492 [33] Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins: Vitamins E and C, beta-carotene,  
493 and other carotenoids. *Ann N Y Acad Sci*. 1992;669:7-20.
- 494 [34] Atef MAA. Hepatoprotective influence of vitamin C on thioacetamide-induced liver cirrhosis in wistar  
495 male rats. *J Pharmacol Toxicol*. 2011;6:218-33.
- 496 [35] Ajayi GO, Adeniyi TT, Babayemi DO. Hepatoprotective and some haematological effects of *Allium*  
497 *sativum* and vitamin C in lead-exposed wistar rats. *Int J Med Med Sci*. 2009;1:64-7.
- 498 [36] Datta G, Basu S, Sen A, Nath P. Role of  $\alpha$ -tocopherol,  $\beta$ -carotene and ascorbic acid against alcohol  
499 induced hepatotoxicity: A comparative analysis. *J Pharm Res*. 2012;5:2485-8.